Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
4.550
+0.040 (0.89%)
At close: Oct 27, 2026, 4:00 PM EDT
4.530
-0.020 (-0.44%)
After-hours: Oct 27, 2026, 7:30 PM EDT
Nuvation Bio Employees
Nuvation Bio had 305 employees as of June 30, 2026. The number of employees increased by 27 or 9.71% compared to the same quarter last year. That makes Nuvation Bio the 23,700th largest employer in the world and 3,054th in the United States.
Employees
305
Change (1Y)
27
Growth (1Y)
9.71%
Revenue / Employee
$557,049
Profits / Employee
-$491,236
Market Cap
1.60B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 305 | 27 | 9.71% |
| Mar 31, 2026 | 307 | 34 | 12.45% |
| Dec 31, 2025 | 298 | 78 | 35.45% |
| Sep 30, 2025 | 291 | 88 | 43.35% |
| Jun 30, 2025 | 278 | 111 | 66.47% |
| Mar 31, 2025 | 273 | 114 | 71.70% |
| Dec 31, 2024 | 220 | 169 | 331.37% |
| Sep 30, 2024 | 203 | 150 | 283.02% |
| Jun 30, 2024 | 167 | 113 | 209.26% |
| Mar 31, 2024 | 159 | 106 | 200.00% |
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Sep 30, 2023 | 53 | -1 | -1.85% |
| Jun 30, 2023 | 54 | -31 | -36.47% |
| Mar 31, 2023 | 53 | -15 | -22.06% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Sep 30, 2022 | 54 | -4 | -6.90% |
| Jun 30, 2022 | 85 | 34 | 66.67% |
| Mar 31, 2022 | 68 | 30 | 78.95% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Novavax | 749 |
| Immunocore Holdings | 524 |
| Intellia Therapeutics | 377 |
| Stoke Therapeutics | 170 |
| Absci | 140 |
| Mesoblast | 108 |
| Nanobiotix | 98 |
NUVB News
- 6 days ago - Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026 - PRNewsWire
- 27 days ago - Nuvation Bio initiated with a Buy at Citi - TheFly
- 5 weeks ago - Nuvation Bio announces FDA approval of sNDA for Ibtrozi - TheFly
- 5 weeks ago - Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer - PRNewsWire
- 6 weeks ago - Nuvation Bio’s Ibtrozi shows durable efficacy in NSCLC studies - TheFly
- 6 weeks ago - Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer - PRNewsWire
- 6 weeks ago - Nuvation Bio Transcript: Cantor Global Healthcare Conference - Transcripts
- 6 weeks ago - Nuvation Bio Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts